CJC 1295 is an incomplete growth hormone, usually in the form of CJC-1295 Acetate. Because cjc 1295 is a slow-release peptide hormone, when CJC is common with other peptide hormones (IGF-1 hGH GHRP-6), it will form a stable covalent bond between them, so as to prolong the continuous onset time of other peptide kinins.In terms of fat reduction, cjc 1295 is very effective. It can not only promote the secretion of self-growth hormone but also promote the secretion of insulin growth factor and thyroxine. Because CJC promotes the secretion of endogenous growth hormone, it will not inhibit the secretion of endogenous growth hormone-like hGH. CJC 1295 can better increase the level of thyroxine in the body, This makes its fat-reducing effect far more than that of growth hormone (hGH). Usually, after injection of CJC for about half an hour, you feel systemic fever due to the increase of self thyroxine.
Package
 |
 |
In essence, using cjc-1295 to make your body produce its own GH is much better than using synthetic GH to turn off your normal production. Then the connection between cjc-1295 and myostatin is that growth hormone directly regulates myostatin. With the increase of growth hormone, myostatin will decrease and release the potential for muscle growth. With the decrease of myostatin, the effect of glucocorticoid on fat storage and muscle decomposition decreased. CJC-1295 Acetate significantly increases GH levels, which will significantly reduce myostatin, thereby reducing the effects of glucocorticoids, fat storage, and muscle decomposition.
Customized Bottle Caps & Corks
|
|
|
CJC-1295 COA
Promotes muscle growth & fat loss:
it in muscle growth and body fat reduction by increasing protein synthesis. This property makes it of interest to athletes and fitness enthusiasts, although its use may be strictly regulated in competitive sports.
Improved Sleep Quality:
Studies have shown that it helps promote deep slow-wave sleep, which is critical for memory retention and rejuvenation.
Enhances Immune System & Bone Density:
By increasing the production of growth hormone, it may help to boost the immune system and improve bone density, thereby combating health problems such as aging and osteoporosis.
Wound Recovery:
It also promotes cell repair and regeneration, including skin and organ cell repair, which helps accelerate the wound recovery process.
Enhancing the function of the immune system, increase the number and activity of white blood cells, and promote the removal of inflammatory factors and tissue repair. Therefore, CJC1295 can be used as a new type of therapeutic drug for chronic inflammation, autoimmune disease, low immunity and other diseases.
CJC1295 plays a protective role in the cardiovascular system, which can increase myocardial contractility, improve myocardial metabolism and protect cardiomyocytes. In addition, CJC1295 can also dilate coronary arteries and peripheral blood vessels, lower blood pressure, and improve heart function. Therefore, CJC1295 can be used as an adjuvant drug for the treatment of heart diseases such as heart failure and coronary heart disease.
We are the supplier of CJC-1295 Acetate.
Remark: BLOOM TECH(Since 2008), ACHIEVE CHEM-TECH is the subsidiary of us.
I. Application Bottlenecks and Technical Demands of GHRH
In the 1980s, the structure and physiological functions of Growth Hormone-Releasing Hormone (GHRH) were elucidated. GHRH can stimulate the pituitary gland to secrete growth hormone (GH) and plays a pivotal role in growth and development, metabolic regulation and other processes. However, natural GHRH suffers from inherent drawbacks including a short half-life (only a few minutes), susceptibility to protease degradation and low bioavailability, which necessitates continuous intravenous infusion and renders it unfit for clinical and research applications.
Starting from the 1990s, pharmaceutical companies and research institutions focused on the structural modification of GHRH to prolong its half-life and enhance its stability. The research team at ConjuChem initiated the development of the CJC-1295 peptide series with GHRH (1-29) as the parent core.
II. Structural Design and Synthesis of CJC-1295 (Late 1990s - Early 2000s)
In 1999, the ConjuChem team synthesized the prototype of CJC-1295 through amino acid sequence optimization and chemical modification. Its core design involves the substitution and modification of amino acids in GHRH (1-29), which enhances resistance to proteases while retaining the activity to stimulate GH secretion. CJC-1295 Acetate, its acetate form, was prepared to improve water solubility and stability.
Studies in this phase confirmed that it could effectively stimulate endogenous GH secretion and had a significantly prolonged half-life (approximately 30 minutes to 2 hours) compared with natural GHRH, laying a solid foundation for subsequent R&D efforts. Meanwhile, the team simultaneously explored long-acting modification technologies, paving the way for the development of CJC-1295 with DAC.
III.Integration of DAC Modification Technology and Positioning of CJC-1295 Acetate (2000-2005)
After 2000, the ConjuChem team developed the Drug Affinity Complex (DAC) modification technology, which enables reversible binding of peptides to serum albumin and drastically extends their half-life. In 2005, the team completed the synthesis of CJC-1295 with DAC. As the non-DAC-modified version, CJC-1295 Acetate became a tool for comparative research to evaluate the impact of DAC modification on the pharmacokinetics and pharmacodynamics of the peptide.
Preclinical studies demonstrated that although CJC-1295 Acetate had a shorter half-life than the DAC-modified variant, it still outperformed natural GHRH. It could elevate the levels of GH and insulin-like growth factor-1 (IGF-1) in a dose-dependent manner with good safety profiles.
IV. Clinical Exploration and Application Expansion (2005-2010)
From 2005 to 2006, ConjuChem conducted early clinical trials of the CJC-1295 series to assess its efficacy in treating HIV-associated muscle wasting, obesity and other diseases. Owing to its moderate half-life, CJC-1295 Acetate was commonly used in short-term intervention and mechanism research, providing a reference for the clinical protocols of the DAC-modified version.
Around 2010, this peptide was widely adopted in basic research in fields such as exercise science and anti-aging. At the same time, its inclusion in the prohibited list by the World Anti-Doping Agency (WADA) spurred the development of detection methods, further clarifying its structural and functional characteristics.
V. Current Status and Significance
To date, CJC-1295 Acetate has not been approved for clinical treatment by the FDA and other regulatory authorities and remains a research-only peptide. Its discovery not only provides a structural optimization paradigm for the development of GHRH analogs but also verifies the feasibility of peptide modification technologies, offering an important reference for the subsequent R&D of long-acting peptide drugs (e.g., liraglutide, dulaglutide). It stands as a typical case marking the leap from "short-acting" to "long-acting" in the history of peptide drug R&D.
Effectiveness Studies:
Scientific studies have shown that it is very effective in increasing growth hormone production and IGF-1 (insulin-like growth factor-1) levels. Increases in these levels help reduce fat and may promote muscle gain.
Safety Studies:
Although it has shown a favorable safety profile in some studies, long-term use may be accompanied by side effects such as pain due to nerve compression, injection site reactions, headache, diarrhea, vasodilation (flushing, fever, transient low blood pressure), nausea, abdominal pain, body water retention, tingling, numbness, insulin decreases, fatigue, and drowsiness. Therefore, it should be fully evaluated and used under the supervision of a physician before use.
Clinical Trials:
Clinical trials of it are currently underway to further evaluate its safety and effectiveness. These trials will help determine its potential role in the treatment of specific diseases.
Status and Challenges
Regulatory Status:
Because CJC-1295 Acetate is not yet widely recognized for medical use, its regulatory status may vary by country and region. In some regions, it may be considered an illegal drug or require special authorization for use.
Dosage and Administration:
Although a number of regimens have been proposed for the use of it, its optimal dosage and administration have not been widely agreed upon in medicine. Therefore, it should be used with caution and following the advice of a medical professional.
Long-Term Effects:
There is still a lack of sufficient data regarding the safety and efficacy of it for long-term use. Therefore, additional studies are needed to assess its long-term effects.
Potential mechanisms and impacts in the association between mitochondrial dysfunction and aging
Aging is a complex biological process that involves multiple levels of molecular and cellular changes. Mitochondrial dysfunction is considered one of the important signs of aging and is closely related to the occurrence and development of various age-related diseases. CJC-1295 Acetate, as a growth hormone releasing hormone (GHRH) analog, stimulates pituitary secretion of growth hormone (GH), which in turn affects downstream signaling pathways such as insulin-like growth factor-1 (IGF-1). It may play a potential role in regulating mitochondrial function and delaying the aging process.
The association between mitochondrial dysfunction and aging
Biological basis of mitochondrial function and aging
Mitochondria are the "energy factories" of cells, responsible for producing ATP through oxidative phosphorylation to provide energy to the cells. As age increases, mitochondrial function gradually declines, manifested as reduced ATP production, decreased mitochondrial membrane potential, and increased production of reactive oxygen species (ROS). These changes lead to cellular energy metabolism disorders, accumulation of oxidative stress damage, and accelerate cellular aging and death.
Mitochondrial dysfunction and age-related diseases
Mitochondrial dysfunction is closely related to the occurrence and development of many aging related diseases, such as neurodegenerative diseases (Alzheimer's disease, Parkinson's disease), cardiovascular diseases, metabolic diseases (diabetes, obesity), etc. In these diseases, mitochondrial dysfunction leads to pathological processes such as energy metabolism disorders, oxidative stress damage, and activation of inflammatory responses, further exacerbating tissue and organ damage and functional decline.
Mitochondrial autophagy and aging
Mitochondrial autophagy is an important mechanism for cells to clear damaged mitochondria and maintain mitochondrial quality homeostasis. As age increases, mitochondrial autophagy function gradually declines, leading to the accumulation of damaged mitochondria, further exacerbating mitochondrial dysfunction and aging processes. Therefore, enhancing mitochondrial autophagy function is considered one of the important strategies for delaying aging and preventing age-related diseases.
Potential role in the association between mitochondrial dysfunction and aging
CJC-1295 Acetate may promote mitochondrial biogenesis and respiratory chain function recovery, increase ATP production, and improve cellular energy metabolism disorders by activating the GH/IGF-1 axis. This helps maintain normal physiological functions of cells and delay the aging process. Mitochondrial dysfunction leads to an increase in ROS production, causing oxidative stress damage. CJC-1295 acetate may improve mitochondrial function, reduce ROS production, and lower levels of oxidative stress damage. In addition, the GH/IGF-1 axis also has antioxidant effects, which can directly clear ROS or enhance the cellular antioxidant defense system, further reducing oxidative stress damage.
Enhance mitochondrial autophagy function and regulate inflammatory response
Although there is currently no direct evidence to suggest that CJC-1295 acetate can enhance mitochondrial autophagy function, the GH/IGF-1 axis plays an important role in regulating autophagy. Research has shown that GH can promote the expression of autophagy related genes and the formation of autophagosomes, thereby enhancing cellular autophagy function. Therefore, CJC-1295 acetate may indirectly enhance mitochondrial autophagy function, clear damaged mitochondria, and maintain mitochondrial mass homeostasis by activating the GH/IGF-1 axis. Mitochondrial dysfunction triggers inflammatory response activation and accelerates the aging process.
CJC-1295 Acetate may reduce inflammatory response levels by improving mitochondrial function and reducing oxidative stress damage. In addition, the GH/IGF-1 axis also has anti-inflammatory effects, which can inhibit the production and release of inflammatory factors and reduce tissue damage caused by inflammatory reactions.
FAQ
What are the downsides to CJC-1295 Ipamorelin?
+
-
Common side effects of CJC1295/Ipamorelin include reactions at the injection site, such as pain, redness or swelling along with flushing of the face; and less than 1 percent of patients report dizziness, headache or hyperactivity.
How many ml of CJC-1295 per day?
+
-
CJC 1295 alone – no DAC o Half-life = approx. 30 minutes o Supplied as 1mg per ml o Dosage = 0.05 ml to 0.1 ml QHS, 5 days out of the week. o It is best to dose CJC 1295 on an empty stomach, at least 2-3 hours after the last meal of the day.
Can a CJC-1295 increase testosterone?
+
-
The peptide CJC-1295 is another option for boosting hGH production which results in increased levels of sex hormones like estrogen or testosterone.
Hot Tags: cjc-1295 acetate cas 863288-34-0, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale, Melanotan ii powder, dermorphin peptide, dermorphin in humans, DERMORPHIN, Cosmetic